Duchenne Muscular Dystrophy (DMD)

DMD: Sarepta Will Pursue Accelerated Approval for Eteplirsen and Conduct Additional Trials

Tadalafil, Sildenafil Increase Blood Flow to DMD-Affected Muscles

A Landmark Development for the Duchenne MD Community

DMD: Prosensa Pursuing Path Forward for Drisapersen

MDA Thrilled FDA Will Consider Accelerated Approval for New Muscle Disease Drug Aimed at DMD

New Forms of Genetic Testing Improve Diagnosis, Raise Questions

“Knowing, if not all, is almost all,” said Matthew Harms, a neurologist and neurophysiologist from Washington University in St. Louis, in his presentation on genetic testing for neuromuscular disorders at the 2014 MDA Clinical Conference, held in Chicago March 16-19.

Shooting for Hope

Artist: 

Bryson is an honor roll student at school. His favorite subjects are reading, spelling and social studies, but sports are his true passion. He collects sports memorabilia. Bryson served two years as MDA’s National Goodwill Ambassador from 2011 – 2013. He and his parents traveled throughout the United States attending events, meeting with sponsors and spreading the message of MDA’s mission. He appeared on the Labor Day Telethon as a co-announcer for two years.

DMD: Phase 2 Drisapersen Results Encouraging

DMD, BMD: Ataluren Did Not Receive Early Approval in Europe

PTC Therapeutics Provides Update On CHMP Opinion For Conditional Approval Of Ataluren For Nonsense Mutation Duchenne Muscular Dystrophy

Pages